The FDA has some questions for Adverum Biotechnologies about the CMC work related to their lead gene therapy for wet, age-related macular degeneration, and regulators have put a clinical hold on their clinical development program until they get some answers. The Menlo Park, CA-based biotech $ADVM reported Monday as the market opened that the agency … Continue reading Adverum Bio offers a late notification about FDA hold on lead gene therapy for wet AMD